Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
about
Maraviroc: a review of its use in HIV infection and beyondResistance against Integrase Strand Transfer Inhibitors and Relevance to HIV PersistenceElevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease OnsetMarkers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.The HIV treatment cascade in acutely infected people: informing global guidelines.A Pilot Study of Raltegravir Plus Combination Antiretroviral Therapy in Early Human Immunodeficiency Virus Infection: Challenges and Lessons Learned.Impact of early cART in the gut during acute HIV infectionVirological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.Factors Associated with the Size of HIV DNA Reservoir.A Mature NK Profile at the Time of HIV Primary Infection Is Associated with an Early Response to cART.Clinical and public health implications of acute and early HIV detection and treatment: a scoping review.Post-Treatment Controllers: Role in HIV "Cure" Research.Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications.Toward Optimal Cryopreservation and Storage for Achievement of High Cell Recovery and Maintenance of Cell Viability and T Cell Functionality.Primary HIV Infection: Clinical Presentation, Testing, and Treatment.NKG2C+ memory-like NK cells contribute to the control of HIV viremia during primary infection: Optiprim-ANRS 147.Impact of early cART on HIV blood and semen compartments at the time of primary infection.Total HIV DNA: a global marker of HIV persistence.Efficacy and safety of boosted darunavir-based antiretroviral therapy in HIV-1-positive patients: results from a meta-analysis of clinical trials.
P2860
Q26778504-81444081-A2C9-4577-A798-66106EDF05DDQ26801286-370DF811-7D9A-4BA8-9A7B-FB694DBFEDACQ36100333-F75D7B03-78A8-420B-BB02-F9C26C2BE4E1Q36509593-71F19766-164C-44F0-AAF7-40D62307B432Q36539990-A1A83AA0-4658-4309-BBA5-2267E9217BC4Q36554974-D564DF04-6F72-41C9-BB03-FADA2917D181Q37109215-44CCF347-ACEA-414C-AFD1-C72F61316A36Q37582477-361BA978-391D-42D1-B754-67EF17832B15Q37615584-4F6A4F79-A6AC-4E14-BB22-1AEBC5B0E322Q37634635-24783A4E-E64A-438D-BD81-54D7279BF06EQ38686953-6A40D5D3-3010-4D0F-ADF3-FCFB8AFFC84CQ38701493-18A5F037-5CBC-4314-B0B6-2D0373D62C4AQ38936786-76DABD4D-DD7F-4406-B126-1A48270D379CQ39736321-A4944A90-65F7-4DB9-AFB3-19614211235BQ40051712-CFC9D6D6-B656-44DE-A91C-6933410084BDQ40089883-8FB99808-0B7D-480E-82DE-A9937688FE91Q40122641-19308714-2A91-4303-8AA2-ACA99B75F559Q54242626-C99C4DAC-318E-4343-9638-75EED2B1152FQ54247051-1F2AAB20-73E1-4603-93B5-E1A89876FE86
P2860
Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@en
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@nl
type
label
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@en
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@nl
prefLabel
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@en
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@nl
P2093
P50
P1476
Intensive five-drug antiretrov ...... ed, open-label, phase 3 trial.
@en
P2093
Adeline Mélard
Alain Lafeuillade
Alain Venet
Antoine Chéret
Bruno Hoën
Caroline Lascoux
Catherine Tamalet
Cécile Goujard
François Raffi
Georges Nembot
P304
P356
10.1016/S1473-3099(15)70021-6
P577
2015-02-18T00:00:00Z